Clinical trials required by European regulators to compare biosimilar products with corresponding biologic brands are surplus to requirements and may even be a barrier for the development of biosimilars of more complicated biologics
Many of the best-selling ‘blockbuster’ biological medicinal products are, or will soon be, facing co...
The European Union (EU) was the first region to establish a regulatory framework for biosimilars, in...
Abstract Biologicals are distinct from small molecule drugs in that they are larger, more structural...
Background: A biosimilar is a biological medicine highly similar to another already approved biologi...
The impending arrival en masse of biosimilars on Western markets is placing drug regulatory agencies...
The concept of biosimilars has spreadfrom Europe to other regions throughout the world, and many reg...
Biosimilars are biological medicinal products marketed as a copy of an originator (reference) produc...
Background: A biosimilar is a biological medicine highly similar to another already approved biologi...
Biosimilars are biological medicinal products marketed as a copy of an originator (reference) produc...
Biomedical products are complex molecules, produced by living cells, molecules that are naturally pr...
20 páginasDeveloping new biologics has led to regulations and norms aimed at guaranteeing their safe...
Biomedical products are complex molecules, produced by living cells. More accurately, they are molec...
Competition arising from the increasing availability of biosimilar medicines has resulted in healthc...
Biosimilar medicinal products (biosimilars) have become a reality in the European Union and will soo...
[[abstract]]Recently, biosimilars have attracted much attention from sponsors and regulatory authori...
Many of the best-selling ‘blockbuster’ biological medicinal products are, or will soon be, facing co...
The European Union (EU) was the first region to establish a regulatory framework for biosimilars, in...
Abstract Biologicals are distinct from small molecule drugs in that they are larger, more structural...
Background: A biosimilar is a biological medicine highly similar to another already approved biologi...
The impending arrival en masse of biosimilars on Western markets is placing drug regulatory agencies...
The concept of biosimilars has spreadfrom Europe to other regions throughout the world, and many reg...
Biosimilars are biological medicinal products marketed as a copy of an originator (reference) produc...
Background: A biosimilar is a biological medicine highly similar to another already approved biologi...
Biosimilars are biological medicinal products marketed as a copy of an originator (reference) produc...
Biomedical products are complex molecules, produced by living cells, molecules that are naturally pr...
20 páginasDeveloping new biologics has led to regulations and norms aimed at guaranteeing their safe...
Biomedical products are complex molecules, produced by living cells. More accurately, they are molec...
Competition arising from the increasing availability of biosimilar medicines has resulted in healthc...
Biosimilar medicinal products (biosimilars) have become a reality in the European Union and will soo...
[[abstract]]Recently, biosimilars have attracted much attention from sponsors and regulatory authori...
Many of the best-selling ‘blockbuster’ biological medicinal products are, or will soon be, facing co...
The European Union (EU) was the first region to establish a regulatory framework for biosimilars, in...
Abstract Biologicals are distinct from small molecule drugs in that they are larger, more structural...
DOI
Add to ORKG